JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
130 hedge funds and large institutions have $243M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 65 increasing their positions, 24 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
36% less capital invested
Capital invested by funds: $378M → $243M (-$135M)
80% less call options, than puts
Call options by funds: $340K | Put options by funds: $1.73M
Holders
130
Holding in Top 10
3
Calls
$340K
Puts
$1.73M
Top Buyers
| 1 | +$4.64M | |
| 2 | +$4.2M | |
| 3 | +$2.29M | |
| 4 |
O
OrbiMed
New York
|
+$2.2M |
| 5 |
Millennium Management
New York
|
+$1.9M |
Top Sellers
| 1 | -$14M | |
| 2 | -$12.6M | |
| 3 | -$10.8M | |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$5.7M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$5.35M |